Hadassah

Hadassah Hosts First Human Trial with Drug to Fight Nasty Bacterial Infection

Monday, Aug 14 2017

Immuron, an Australian biopharmaceutical company, has received approval from the Hadassah Medical Organization’s ethics committee and Israel’s Ministry of Health to begin its first clinical trial with a new drug to fight a bacterial infection called Clostridium Difficile (CDI).

CDI, often also called C. difficile, is caused by a bacterial toxin that inflames the colon. It is especially found in hospitals and long-term, in-patient care facilities. Approximately 500,000 people annually contract CDI in the U.S. alone and about 20 percent experience a recurrence.

The new product, called IMM-529, is a naturally produced biological antibody, intended to prevent and treat CDI, as well as stop recurrence. As a polyclonal antibody, it generates highly specific antibodies to fight the three main sources of CDI: Toxin B, the highly infectious spores, and the vegetative cells in the gut. In addition, IMM-529 has been shown to rebalance the diversity of bacteria in the gut, which is often disrupted by antibiotics.

This first-ever human study will assess whether IMM-529 is safe and well tolerated by the participants and will also evaluate the preliminary efficacy of IMM-529. Pre-clinical studies with mice at Monash University in Melbourne, Australia, revealed 80 percent efficacy in preventing and treating CDI and 77.8 percent success in preventing recurrence. The control group of mice, in contrast, which only received the standard-of-care antibiotic, vancomycin, experienced a mortality rate of 88.9 percent.

In this human trial, 60 patients who have been diagnosed with CDI and treated with standard-of-care antibiotics, will be enrolled within three weeks of their diagnosis. Some will be randomly selected to receive IMM-529 three times daily and the others will receive a placebo for 28 days.

Read more at: http://www.immuron.com/assets/Uploads/Red-Chip-C-Difficile-Analyst-Report-Jan-2016.pdf

Read about another IMMURON clinical trial at Hadassah http://www.hadassah.org/news-stories/fatty-liver-us-trials.html

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Feb 14 2018

Student with MS Running the Jerusalem Marathon to Support Hadassah’s MS Program

Thanks to his physicians at the Hadassah Medical Center, Dov Guggenheim, who was diagnosed with Multiple Sclerosis (MS) in 2015, has gone from “depressed to optimistic, paralyzed to athletic, and, most important, hopeless to hopeful.”

READ MORE ›
alt_text

Wednesday, Feb 7 2018

Texas Tropical Disease Expert Meets with Hadassah Infectious Disease Specialists

Dr. Peter Jay Hotez, renowned professor in the Departments of Pediatrics and Molecular Virology and Microbiology at Houston (Texas) Baylor College of Medicine and Dean of its National School of Tropical Medicine, met with two Hadassah Medical Organization infectious disease specialists to discuss regional cooperation in fighting tropical diseases, such as the now-infamous Zika virus and leishmaniosis, which is contracted from sand flies.

READ MORE ›
alt_text

Wednesday, Feb 7 2018

Large Hadassah Study Identifies Predictor of Greater Risk of End-Stage Renal Disease

The findings of a nationwide study of over a million and a half Israeli adolescents, conducted by researchers at the Hadassah-Hebrew University Braun School of Public Health and Community Medicine, suggest that kidney disease in childhood is associated with a significantly increased risk of end-stage renal disease (ESRD) in adulthood, even if kidney function seems normal in adolescence.

READ MORE ›
alt_text

Wednesday, Feb 7 2018

Israeli Start-up’s Algorithm Predicts Which Diabetic Patients Will Suffer Kidney Dysfunction Within One Year

The Israeli start-up Medial EarlySign has created a machine-learning-based model that has proven to identify diabetic patients who are at the highest risk for experiencing renal dysfunction within one year.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More